VivoSeq
Other

Fluorouracil

0

Pipeline Programs↗

4

Active Trials↗

4

Companies Involved↗

Fluorouracil is an early-stage landscape with 0 programs across 4 companies. The most active players are Sanofi, Eli Lilly, Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

72/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalS

Spear Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

27

clinical trials

Completed13 · 48%
Terminated5 · 19%
Unknown status5 · 19%
Recruiting2 · 7%
Active, not recruiting1 · 4%
Not yet recruiting1 · 4%

Clinical Trials

Trial Activity

27 trials

Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
Recruiting·UUniversity of Washington·Phase 3·NCT02025023·120 enrolled
Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC
Recruiting·—·Phase 1·NCT03370406·30 enrolled
Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00707473·31 enrolled
5-Fluorouracil Response and Optimization STudy (The FROST Trial)
Not yet recruiting·WWashington University School of Medicine·Phase 2·NCT07419464·46 enrolled
Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination
Completed·Sanofi logoSanofi·Phase 1·NCT00507091·24 enrolled
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
Completed·Eli Lilly logoEli Lilly·Phase 1·NCT01286818·6 enrolled
Fluorouracil Filtering Surgery Study (FFSS)
Completed·National Eye Institute (NEI)·Phase 3·NCT00000122
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT01046864·49 enrolled
Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer
Completed·AAIO-Studien-gGmbH·Phase 2·NCT03044587·93 enrolled
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT00610948·74 enrolled
Bioequivalence Study of Generic Fluorouracil 0.5% Cream and 0.5% Carac® and Placebo
Completed·SSpear Pharmaceuticals·Phase 3·NCT01354717·377 enrolled
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, Leucovorin, and Avastin
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00507585·63 enrolled
Surgical Excision Versus Photodynamic Therapy and Topical 5-fluorouracil in Treatment of Bowen's Disease
Completed·MMaastricht University Medical Center·Phase 4·NCT03909646·250 enrolled
5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts
Completed·MMassachusetts Eye and Ear Infirmary·Phase 2·NCT02705352·1 enrolled
Measuring Adherence To Topical 5-Fluorouracil in a Clinic Population
Completed·WWake Forest University·Phase 4·NCT00696488·20 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)